AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9495408
Drug: no droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: no droperidol injection
Trial: 300048
Drug: Sulindac (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (twice daily dosage for 5 days)
Trial: 300048
Drug: Sulindac (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (twice daily dosage)
Trial: 23973636
Drug: American ginseng
RxNorm normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: American ginseng (AG) 3g daily for 12 weeks
Trial: 20713813
Drug: Narrowband UV-B
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband UV-B treatment 3 times per week
Trial: 12093831
Drug: OC +
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC + metformin
Trial: 9560053
Drug: Full-dose anthracycline-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose anthracycline-containing regimens similar to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Trial: 9560053
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of CHOP chemotherapy followed by involved field irradiation
Trial: 9560053
Drug: Hematopoietic growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematopoietic growth factors and/or cardioprotective drugs
Trial: 7643821
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ketoprofen lysine salt suppositories
Trial: 7643821
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketoprofen lysine salt suppositories
Trial: 7643821
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ketoprofen lysine salt suppositories
Trial: 7643821
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ketoprofen lysine salt suppositories
Trial: 7643821
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ketoprofen lysine salt suppositories
Trial: 2751841
Drug: Ketotifen 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 0.35 mg every 12 hours
Trial: 782977
Drug: Oral killed
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral killed typhoid vaccine (100.10^9 killed S. typhi)
Trial: 782977
Drug: Oral killed
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral killed typhoid vaccine (300.10^9 killed S. typhi)
Trial: 782977
Drug: Oral killed
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral killed typhoid vaccine (400.10^9 killed S. typhi)
Trial: 31302768
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: IANB and buccal infiltration (BI) of 4% articaine
Trial: 31302768
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: IANB + BI and intraseptal injection of articaine
Trial: 29703998
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OXT) administration
Trial: 29703998
Drug: Placebo (PLC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLC) administration
Trial: 28370178
Drug: Curcuma (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma (6 g containing 2% curcumin)
Trial: 26438237
Drug: Short-term fasting
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term fasting (STF) 24 hours before and after chemotherapy
Trial: 19808351
Drug: Serial B-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial B-type natriuretic peptide testing (at 3, 6, 9, and 12 hours then daily)
Trial: 11435883
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (240 ml, 3 times daily for 7 days)
Trial: 11435883
Drug: Control (tap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (tap water, 240 ml, 3 times daily for 7 days)
Trial: 9682700
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with early worsening
Trial: 9682700
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment initiation
Trial: 28801967
Drug: Experimental retreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental retreatment with subcutaneous bortezomib plus dexamethasone (VD)
Trial: 24345356
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual with smoking-cessation treatment (weekly individual smoking cessation counseling and extended-release bupropion 300 mg/d during weeks 1-10, nicotine inhaler and contingency management for smoking abstinence during weeks 4-10)
Trial: 24345356
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual with smoking-cessation treatment
Trial: 12492746
Drug: Forlax (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forlax (10 g)
Trial: 12492746
Drug: Forlax (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forlax (20 g)
Trial: 12492746
Drug: Transipeg (5.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transipeg (5.9 g)
Trial: 12492746
Drug: Transipeg (11.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transipeg (11.8 g)
Trial: 9337835
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of gas mixtures with varying fractional inspired oxygen concentration (FiO2) from 0.1 to 1.0
Trial: 9337835
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of gas mixtures with FiO2 of 0.1
Trial: 8449125
Drug: Antioxidant vitamins
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamins (vitamin A 30,000 IU/day, vitamin C 1 g/day, vitamin E 70 mg/day)
Trial: 8449125
Drug: Lactulose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (20 g/day)
Trial: 2869676
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 to 160 mg 3 times a day)
Trial: 2869676
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 to 120 mg 3 times a day)
Trial: 29864732
Drug: Telephone-delivered mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered mindfulness-based cognitive therapy (MBCT-T)
Trial: 18803955
Drug: Telmisartan 47.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 47.0 mg/d
Trial: 18803955
Drug: Candesartan 8.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8.4 mg/d
Trial: 18803955
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no change in drug regimen)
Trial: 16169302
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg nicotine enema
Trial: 16169302
Drug: Nicotine therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine therapy
Trial: 11974560
Drug: CEE/MPA 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA 0.625 mg-5.0 mg daily for 13 treatment cycles (28 days each)
Trial: 11974560
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg daily for 13 treatment cycles (28 days each)
Trial: 10482696
Drug: Superselective intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Superselective intra-arterial chemotherapy
Trial: 10482696
Drug: Systemic intravenous
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic intravenous chemotherapy
Trial: 6163166
Drug: gamma-globulin/histamine complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma-globulin/histamine complex by subcutaneous injection
Trial: 6163166
Drug: active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active treatment (gamma-globulin/histamine complex)
Trial: 31881879
Drug: High-energy dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy dose TUS combined with a rehabilitation program
Trial: 11738336
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of levofloxacin 500 mg once daily
Trial: 11738336
Drug: 7-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of levofloxacin 500 mg once daily
Trial: 9463638
Drug: Losartan (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (selective AT1 receptor antagonist)
Trial: 8505747
Drug: Acetard 300
RxNorm normalized name: lanreotide
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acetard 300 mg
Trial: 8505747
Drug: Acetard 100
RxNorm normalized name: flecainide acetate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetard 100 mg
Trial: 8505747
Drug: Platet 100
RxNorm normalized name: PLATELET GLYCOPROTEIN VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platet 100 mg
Trial: 3691010
Drug: Two 5‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 5‐mg tablets (Treatment A)
Trial: 3691010
Drug: One 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 10‐mg tablet (Treatment B)
Trial: 3691010
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of a 1‐mg/mL suspension (Treatment C)
Trial: 3691010
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of a 1‐mg/mL aqueous reference solution (Treatment D)
Trial: 3691010
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between Treatment A and Treatment D
Trial: 3691010
Drug: Bioequivalence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioequivalence of dosage forms
Trial: 30955362
Drug: Pedometer worn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer worn on the hip with visible step count and daily recording
Trial: 23926679
Drug: Spermatic cord
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermatic cord seal-up injection (lidocaine, gentamicin or Amikacin, dexamethasone), qd or bid, for 2 courses of 5 days each, with an interval of 3 to 5 days.
Trial: 23926679
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment (intravenous drip of penicillin, qd; intramuscular injection of Streptomycin, bid; oral SMZCo, bid, with initial dose doubled).
Trial: 15387802
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eccentric exercises and night splint
Trial: 11212044
Drug: Remifentanil iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil iv followed by a continuous infusion of 0.25 to 0.50 microg x kg(‐1) x min(‐1)
Trial: 9771298
Drug: Hydroxyzine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (1 mg kg‐1)
Trial: 28235621
Drug: Low-dose CAP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CAP (2 mg/d; L-CAP, n = 27)
Trial: 28235621
Drug: High-dose CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CAP (4 mg/d; H-CAP, n = 22)
Trial: 25963985
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g GSR‐PAS twice daily
Trial: 25963985
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g GSR‐PAS once daily
Trial: 23433101
Drug: Everolimus 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 1.5 mg with reduced-dose cyclosporine
Trial: 23433101
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 3 g/day with standard-dose cyclosporine
Trial: 21615449
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) treatment for 15 months
Trial: 21615449
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) treatment in mice with EAE
Trial: 19062230
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol and ipratropium with warmed humidified oxygen
Trial: 19062230
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol and ipratropium with humidified oxygen at room temperature
Trial: 19062230
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol with warmed humidified oxygen
Trial: 19062230
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol with humidified oxygen at room temperature
Trial: 29229305
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (50,000 IU weekly for 12-14 weeks)
Trial: 28853392
Drug: Sertraline prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline prescribed in therapeutic doses for 12 months
Trial: 28853392
Drug: High-intensity Cognitive
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity Cognitive Behavioural Therapy (CBT) delivered in 14 sessions
Trial: 23571176
Drug: HPV‐16/18 AS04‐adjuvated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐16/18 AS04‐adjuvated vaccine
Trial: 18339153
Drug: 2 mg/ml
RxNorm normalized name: urea 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/ml of both morphine and ketamine (Ketamine group, n=26)
Trial: 18339153
Drug: 2 mg/ml
RxNorm normalized name: urea 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/ml of morphine (Control group, n=30)
Trial: 16362788
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (68-MeV protons)
Trial: 7559293
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 10 mg bid
Trial: 7559293
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 20 mg bid
Trial: 419163
Drug: Psychotropic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drugs (20 different types)
Trial: 27209164
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus Bevacizumab (150 mg daily of erlotinib and 15 mg/kg of bevacizumab intravenously on day 1 of every 21-day cycle)
Trial: 24039147
Drug: Instant pure
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant pure soluble coffee (three increasing doses)
Trial: 20619460
Drug: Topical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prostaglandin analog (PGA) in 1 eye
Trial: 12809961
Drug: Tramadol 37.5
RxNorm normalized name: ACETAMINOPHEN 325MG/TRAMADOL 37.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 37.5 mg/APAP 325 mg combination tablets
Trial: 8866038
Drug: Zenith Laboratories
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zenith Laboratories nicardipine (30 mg) under fasted conditions
Trial: 31727154
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mDCs and pDCs vaccination
Trial: 31727154
Drug: All DC
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All DC vaccines
Trial: 7588499
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) replacement therapy for 3 months
Trial: 7955441
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) replacement therapy
Trial: 30986513
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy (scaling and root planing) during the first 6 months
Trial: 20537140
Drug: Self-reported medication
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported medication side effects
Trial: 20537140
Drug: Risk factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factors for medication side effects
Trial: 20537140
Drug: Liver problems
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver problems and doctor's awareness of medications
Trial: 15860043
Drug: Tenecteplase (weight-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (weight-adjusted dose)
Trial: 12375548
Drug: Chlorhexidine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.2% vaginal flushings (140 ml every 6 hours until delivery)
Trial: 12375548
Drug: Ampicillin 2
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 g intravenously (every 6 hours until delivery)
Trial: 1724166
Drug: MK886 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK886 (oral leukotriene biosynthesis inhibitor)
Trial: 29549104
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg of 0.1% E2 gel per day
Trial: 17766739
Drug: IV NTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV NTG (initial dose of 0.05 microg.kg(‐1).min(‐1), followed by 0.1 microg.kg(‐1).min(‐1))
Trial: 15240604
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from T(4) therapy
Trial: 15240604
Drug: No transient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No transient therapy with T(3)
Trial: 12097994
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream (Elidel)
Trial: 7936174
Drug: Gadodiamide injection
RxNorm normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadodiamide injection at 0.1 mmol/kg body weight
Trial: 7936174
Drug: Gadodiamide injection
RxNorm normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadodiamide injection at 0.3 mmol/kg body weight
Trial: 7936174
Drug: Gadodiamide injection
RxNorm normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadodiamide injection (both doses)
Trial: 3337574
Drug: Lotion soap
RxNorm normalized name: Medicated Lotion Soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion soap (Safe 'N Sure)
Trial: 1493935
Drug: Low-dose AraC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose AraC (2 x 10 mg/m2 subcutaneously days 1‐14) plus GM-CSF (2 x 150 micrograms protein/day subcutaneously)
Trial: 835531
Drug: Boric acid-sodium
RxNorm normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boric acid-sodium borate solution
Trial: 31733045
Drug: Podiatry intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podiatry intervention (3 visits, foot orthoses, exercise, manual therapy, advice)
Trial: 31733045
Drug: Usual GP
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual GP care (1 visit, medication advice/prescription, same advice as podiatry group)
Trial: 30312162
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with standard-of-care pain treatment